Multipleendocrine neoplasia type 1 (MEN1) is an autosomal dominant condition that includesa varying combination of more than 20 endocrine and non-endocrine tumors.Endocrine tumors associated with MEN1 include parathyroid tumors, pituitarytumors, well-differentiated endocrine tumors of the gastro-entero-pancreatic(GEP) tract, carcinoid tumors, and adrenocortical tumors. These tumors canbecome evident by overproduction of hormones by the tumor or by growth of thetumor itself. Non-endocrine tumors associated with MEN1 syndrome include facialangiofibromas, collagenomas, lipomas, meningiomas, ependymonas, and leiomyomas.
Parathyroidtumors are the main MEN1-associated endocrinopathy with onset in 90% ofindividuals at 20-25 years of age and manifest as hypercalcemia by age 50years. Prolactinoma is the most common pituitary tumor. GEP tract endocrinetumors include gastrinoma, insulinoma, glucagonoma, and VIPoma. Carcinoidtumors are non-hormone-secreting and manifest as a large mass after age 50years. Adrenocortical tumors are associated with primary hypercortisolism orhyperaldosteronism.
Approximately88% of affected individuals will have facial angiofibromas, which are benigntumors comprising blood vessels and connective tissue. These consist ofacneiform papules that do not regress and that may extend across the vermillionborder of the lips. Collagenomas are seen in about in 72% of affectedindividuals and are multiple, skin-colored, sometimes hypopigmented, cutaneiousnodules symmetrically arranged on the trunk, neck, and upper limbs. They aretypically asymptomatic, roundish, and firm-elastic, from a few millimeters toseveral centimeters in size.
Clinicaldiagnostic criteria for MEN1 include the presence of two endrocrine tumors thatare parathyroid, pituitary, or GEP tract tumors. Familial MEN1 is defined as MEN1 in an individual who has either at least one first-degreerelative with at least one of these endocrine tumors or only one organ involvement and an MEN1disease-causing germline mutation. Molecular genetictesting of MEN1(11q13), the only gene known to be associated with MEN1, detects MEN1 mutations in about 80-90%of probands with familial MEN1 and in about 65% of individuals with a single occurrence of MEN1 in thefamily. Approximately 10% of cases are caused by de novo mutations.
For patients with suspected MEN1, sequence analysis is recommended as the first step in mutation identification. For patients in whom mutations are not identified by full gene sequencing, deletion/duplication analysis is appropriate.
Click here for the GeneTests summary on this condition.
This test is indicated for:
- Confirmation of a clinical/biochemical diagnosis of MEN1
- Individuals at-risk for MEN1 due to family history
Clinical Sensitivity: 80-90% in individuals with familial MEN1 and 65% in individuals with no family history. Mutations in the promoter region, some mutations in the introns and other regulatory element mutations cannot be detected by this analysis. Large deletions will not be detected by this analysis. Results of molecular analysis should be interpreted in the context of the patient's biochemical phenotype.
Analytical Sensitivity: ~99%
Isolation using the Perkin Elmer™Chemagen™ Chemagen™ Automated Extraction method or Qiagen™ Puregene kit for DNA extraction is recommended.
Infants and Young Children (<2 years of age): 2-3 ml
Children > 2 years of age to 10 years old: 3-5 ml
Older Children & Adults: 5-10 ml
Autopsy: 2-3 ml unclotted cord or cardiac blood
Orangene™ Saliva Collection Kit used according to manufacturer instructions. Please contact EGL for a Saliva Collection Kit for patients that cannot provide a blood sample.
Submit copies of diagnostic biochemical test results with the sample, if appropriate. Contact the laboratory if further information is needed.
Sequence analysis is required before deletion/duplication analysis by targeted CGH array. If sequencing is performed outside of EGL Genetics, please submit a copy of the sequencing report with the test requisition.
- Deletion/duplication analysis of the MEN1 gene by CGH array is available for those individuals in whom sequence analysis is negative (VS).
- Custom diagnostic mutation analysis (KM) is available to family members if mutations are identified by targeted mutation testing or sequencing analysis.
- Prenatal testing is available to individuals who are confirmed carriers of mutations. Please contact the laboratory genetic counselor to discuss appropriate testing prior to collecting a prenatal specimen.